From low-end production to high-end manufacturing, "domestic power" is rising

[ Chemical Machinery Equipment Network Market Analysis ] With the aging and the growth of people's demand for medicines, the pharmaceutical equipment market has huge potential.
Data shows that the current market size of my country's pharmaceutical equipment industry is about 50 to 60 billion yuan.
With the increasing population aging, the demand for pharmaceuticals is expected to maintain rapid growth, which will drive the sustainable development of the pharmaceutical equipment industry.

At the same time, with the acceleration of the transformation and upgrading of the pharmaceutical industry, fixed asset investment in the pharmaceutical manufacturing industry has ushered in growth.
According to the National Bureau of Statistics, the national investment in fixed assets (excluding rural households) in 2020 will be 5,18907 trillion yuan, an increase of 2.
9% over the previous year.
Among them, the pharmaceutical manufacturing industry grew rapidly, with investment increasing by 28.
4% over the previous year.
From January to April 2021, fixed asset investment in the pharmaceutical manufacturing industry also achieved a year-on-year growth of 33.
1%.
In this context, the industry believes that the pharmaceutical industry is also expected to fully benefit, and the future market space is huge.

The huge potential of China's pharmaceutical machinery market has attracted the layout of many domestic and foreign manufacturers.
In the past, the domestic pharmaceutical machinery market, especially the high-end market, basically relied on imported equipment.
In recent years, with the development of science and technology, local pharmaceutical machinery companies have continued to increase their investment in innovation, aiming at mid-to-high-end areas, and continue to tackle key problems and grow.
The Jiufang Financial Research Institute released a research report that after ten years of industrial chain development, domestic pharmaceutical equipment companies have gradually become a subdivision of China's high-end manufacturing, domestic substitution has accelerated, export overseas business has grown rapidly, and the industry has gradually faded away from its cyclical nature.
Long-term growth.  

　　It can also be seen from the pharmaceutical machinery event in recent years that the "domestic power" in the field of pharmaceutical equipment is rising day by day.
According to overseas reports, at the Pharmaceutical Machinery Expo this spring, not only METTLER TOLEDO, Intech, Mankenberg, Uman, Sikari, Meyer and other overseas companies participated, but also Xinhua Medical, Local companies such as Jiangsu Treasure, Shanghai Tianxiang, Heilongjiang Deere, Harbin Nano, Beijing Shuanghe, Ruian Hualian, Zhoukou Pharmaceutical Machinery, Dongfulong, Chutian Technology, Beijing Hanlin, Zhejiang Canaan, Zhejiang Hope, Liaoning Chunguang, etc.
Appeared, more and more local enterprises shined at the Expo, helping China's pharmaceutical equipment industry to develop and grow.  

　　It is worth noting that after years of rapid development, the domestic pharmaceutical equipment industry has developed more and more steadily, but it still faces many challenges.
The main characteristics are "small", "scattered", and "chaotic".
There are a large number of companies in the market, but most of them are small and medium-sized, with enterprises above the industry scale, and large enterprises accounting for a relatively small proportion; products on the market are mixed.
, Quality is uneven; enterprises still need to strengthen their awareness of intellectual property protection.  

　　In addition, my country's pharmaceutical equipment products are still dominated by low-end products.
Compared with imported equipment, my country's pharmaceutical machinery manufacturers have a large gap in production technology, equipment level, and production technology.
Most small and medium-sized enterprises in the industry still mainly produce low-end, low-level products, and the quality and performance of products of larger enterprises are still far from those of developed countries in Europe and America.
In addition, in terms of R&D investment, the R&D investment of large domestic pharmaceutical companies accounts for about 5-10% of revenue.
Compared with European and American countries, R&D investment is still relatively low, and more policy support and corporate attention are needed.  

　　In September 2020, the National Development and Reform Commission and other four departments jointly issued the "Guiding Opinions on Expanding Investment in Strategic Emerging Industries, Cultivating and Growing New Growth Pole Growth Pole", which proposed to focus on supporting the production of high-end equipment such as high-end medical equipment and pharmaceutical equipment and implementing intelligent manufacturing , Pilot demonstration of intelligent construction.
For the pharmaceutical equipment industry, the release of this heavy document will help promote the development of the domestic pharmaceutical machinery industry towards high-end development.

 

　　In general, moving from low-end production to high-end manufacturing is a major development trend in the pharmaceutical industry.
However, there is still a long way to go for domestic pharmaceutical machinery to reach the high-end.
While seeing opportunities, major pharmaceutical machinery companies should also establish firm beliefs, maintain confidence, be down-to-earth, continue to innovate and develop, and continue to achieve high industrial quality.
A new level of development.  

　　Original title: From low-end production to high-end manufacturing, "domestic power" in the field of pharmaceutical equipment is rising